Associations of Plasma Biomarkers with Cerebral Perfusion and Structure in Alzheimer's Disease

Overview

Journal Transl Psychiatry

Specialties Psychiatry
Public Health

Date 2025 Jan 6

PMID 39762217

Authors

Yong He

Xiaojiao Liu

Fang Liu

Ping Che

Yanxin Zhang

Ruxue Fan

Yuan Li

Wen Qin

Nan Zhang

Affiliations

Soon will be listed here.

Abstract

Plasma biomarkers have great potential in the screening, diagnosis, and monitoring of Alzheimer's disease (AD). However, findings on their associations with cerebral perfusion and structural changes are inconclusive. We examined both cross-sectional and longitudinal associations between plasma biomarkers and cerebral blood flow (CBF), gray matter (GM) volume, and white matter (WM) integrity. Forty-eight AD patients whose diagnosis was supported by amyloid-β (Aβ) PET received measurement of plasma biomarkers with a single molecular array, including Aβ42, phosphorylated tau 181 (P-tau181), neurofilament light (NfL), total tau (T-tau), and glial fibrillary acidic protein (GFAP), and both baseline and one-year follow-up magnetic resonance imaging, including pseudo-continuous arterial spin labeling, T1-weighted imaging, and diffusion tensor imaging. Correlations were found between regional CBF and several plasma biomarkers, with Aβ42 showing the strongest correlation with CBF in the left inferior temporal gyrus (r = 0.507, p = 0.001). Plasma P-tau181 and GFAP levels were correlated with GM volume in the posterior cingulate gyrus and the bilateral hippocampus and right middle temporal gyrus, respectively. Decreased CBF and GM volume in regions vulnerable to AD, such as the posterior cingulate gyrus, inferior parietal lobule and hippocampus, could be predicted by the levels of specific plasma biomarkers. Most biomarkers, except Aβ42, showed extensive correlations with longitudinal WM disruption. Plasma biomarkers exhibited varied correlations with brain perfusion, GM volume, and WM integrity and predicted their longitudinal changes in AD patients, suggesting their potential to reflect functional and structural changes and to monitor pathophysiological progression in the brain.

References

Mattsson N, Tosun D, Insel P, Simonson A, Jack Jr C, Beckett L . Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain. 2014; 137(Pt 5):1550-61. PMC: 3999717. DOI: 10.1093/brain/awu043. View

Teunissen C, Verberk I, Thijssen E, Vermunt L, Hansson O, Zetterberg H . Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2021; 21(1):66-77. DOI: 10.1016/S1474-4422(21)00361-6. View

OBryant S, Mielke M, Rissman R, Lista S, Vanderstichele H, Zetterberg H . Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2016; 13(1):45-58. PMC: 5218961. DOI: 10.1016/j.jalz.2016.09.014. View

Deters K, Risacher S, Kim S, Nho K, West J, Blennow K . Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. J Alzheimers Dis. 2017; 58(4):1245-1254. PMC: 5523909. DOI: 10.3233/JAD-161114. View

Wang Y, West J, Flashman L, Wishart H, Santulli R, Rabin L . Selective changes in white matter integrity in MCI and older adults with cognitive complaints. Biochim Biophys Acta. 2011; 1822(3):423-30. PMC: 3235544. DOI: 10.1016/j.bbadis.2011.08.002. View

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim S . The Amyloid-β Pathway in Alzheimer's Disease. Mol Psychiatry. 2021; 26(10):5481-5503. PMC: 8758495. DOI: 10.1038/s41380-021-01249-0. View

McDade E, Kim A, James J, Sheu L, Kuan D, Minhas D . Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology. 2014; 83(8):710-7. PMC: 4150128. DOI: 10.1212/WNL.0000000000000721. View

Park J, Hong J, Lee S, Ji H, Jung J, Yoon K . The effect of chronic cerebral hypoperfusion on the pathology of Alzheimer's disease: A positron emission tomography study in rats. Sci Rep. 2019; 9(1):14102. PMC: 6773854. DOI: 10.1038/s41598-019-50681-4. View

Mattsson N, Zetterberg H, Janelidze S, Insel P, Andreasson U, Stomrud E . Plasma tau in Alzheimer disease. Neurology. 2016; 87(17):1827-1835. PMC: 5089525. DOI: 10.1212/WNL.0000000000003246. View

10.

Moscoso A, Grothe M, Ashton N, Karikari T, Rodriguez J, Snellman A . Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurol. 2021; 78(4):396-406. PMC: 7802009. DOI: 10.1001/jamaneurol.2020.4986. View

11.

Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K . Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage. 2008; 40(2):570-582. PMC: 2478641. DOI: 10.1016/j.neuroimage.2007.12.035. View

12.

Middeldorp J, Hol E . GFAP in health and disease. Prog Neurobiol. 2011; 93(3):421-43. DOI: 10.1016/j.pneurobio.2011.01.005. View

13.

Brueggen K, Dyrba M, Cardenas-Blanco A, Schneider A, Fliessbach K, Buerger K . Structural integrity in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease based on multicenter diffusion tensor imaging. J Neurol. 2019; 266(10):2465-2474. DOI: 10.1007/s00415-019-09429-3. View

14.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

15.

Weijs R, Shkredova D, Brekelmans A, Thijssen D, Claassen J . Longitudinal changes in cerebral blood flow and their relation with cognitive decline in patients with dementia: Current knowledge and future directions. Alzheimers Dement. 2022; 19(2):532-548. DOI: 10.1002/alz.12666. View

16.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

17.

Sabuncu M, Desikan R, Sepulcre J, Yeo B, Liu H, Schmansky N . The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011; 68(8):1040-8. PMC: 3248949. DOI: 10.1001/archneurol.2011.167. View

18.

Bettcher B, Olson K, Carlson N, McConnell B, Boyd T, Adame V . Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease. Neurobiol Aging. 2021; 103:68-77. PMC: 8313091. DOI: 10.1016/j.neurobiolaging.2021.02.012. View

19.

Dong H, Guo L, Yang H, Zhu W, Liu F, Xie Y . Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer's disease. Front Aging Neurosci. 2023; 15:1129051. PMC: 10117777. DOI: 10.3389/fnagi.2023.1129051. View

20.

Chen Y, Wang Y, Song Z, Fan Y, Gao T, Tang X . Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: A systematic review. Ageing Res Rev. 2023; 87:101911. DOI: 10.1016/j.arr.2023.101911. View